Drugs / REZORSTOBART
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05565417 | Nov 2022 → Jan 2026 overdue | Burkitt lymphoma, Hodgkins lymphoma, colorectal cancer, diffuse large B-cell lymphoma +8 | Immunitas Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REZORSTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314872 ↗ |
| Known as | IMT-009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05565417 ↗ |
| Action | Inhibit | “Preclinical data confirm that CD161 blockade with IMT-009 results in enhanced anti-tumor activity” NCT05565417 ↗ |
| Modality | Monoclonal antibody | “IMT-009 is an Fc-attenuated monoclonal antibody” NCT05565417 ↗ |
| Route | Intravenous | “Participants will receive an IV infusion of IMT-009 on Day 1 during each 21-day cycle.” NCT05565417 ↗ |